Fluent Commerce vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Sydney cloud-native distributed order management system founded 2013; raised $30M+; routes orders across warehouses, stores, and drop-ship vendors in real time for omnichannel retailers.
About
Fluent Commerce was founded in 2013 in Sydney, Australia and raised over $30M to build a cloud-native distributed order management system (DOM) designed for large omnichannel retailers. The company's platform solves one of the most operationally complex challenges in modern retail: routing customer orders to the optimal fulfillment location across a network that may include warehouses, stores, drop-ship vendors, and third-party logistics partners, in real time and at scale.\n\nFluent Order Management is built as a highly configurable, API-first platform that allows retailers to model their unique fulfillment network and define custom orchestration rules without requiring code changes. This flexibility makes it suitable for complex retail operations where a pre-built rules engine would be too rigid. The platform handles order capture, inventory availability checking, fulfillment location selection, shipment tracking, and returns management, with a store fulfillment module that enables buy-online-pick-up-in-store (BOPIS) and ship-from-store capabilities.\n\nFluent Commerce counts major global retailers among its customers and competes against IBM Sterling, Blue Yonder, and Manhattan Associates in the enterprise DOM market, as well as against newer competitors like Kibo Commerce. Its differentiation lies in the combination of a truly cloud-native architecture — contrasted with the legacy on-premise roots of many DOM incumbents — and a partner ecosystem that makes implementation more accessible for retailers without large internal IT teams.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.